Recent Articles
Biotech Movers: Chelsea Doubles, Vivus Dips
Feb. 25, 2013, 9:15 am EDT – Last week, Vivus slipped on a rejection from European regulators. Plus, find out why Chelsea Therapeutics and Infinity Pharmaceuticals soared. More
Biotech Movers: Big Bumps All Around
Feb. 19, 2013, 8:30 am EDT – Last week, big names from Ziopharm Oncology to StemCells posted stellar gains, while Amicus Therapeutics shaked the positive trend with a hearty tumble. More
Still Wild for BWLD
Feb. 14, 2013, 11:27 am EDT – Sure, the company faces headwinds -- uncertainty about the minimum wage and higher input costs among them -- but Buffalo Wild Wings has carved out a dedicated niche that's unlikely to fade anytime soon. More
Top 10 Dow Dividend Stocks for February
Feb. 11, 2013, 2:08 pm EDT – Income investors could do a lot worse than buying into these venerable blue chips -- especially the stock that continues to hold the crown. More
Biotech Movers: A Doubler for Opexa
Feb. 11, 2013, 8:30 am EDT – A good week for little guys Opexa Therapeutics and Hyperion Therapeutics and giant Biogen. But Hemispherx BioPharma and BioCryst Pharmaceuticals had downers. More
The Wide World of Sports Investing
Feb. 4, 2013, 11:29 am EDT – If you're missing the excitement of sports after Sunday's Super Bowl, the finance world offers you plenty of sports-related stocks ... you just might pick a winner for your portfolio. More
Biotech Movers: Keryx Jumps, Sarepta Slips
Feb. 4, 2013, 8:15 am EDT – Among last week's highlights, Keryx jumps on a solid Phase III trial, Sarepta gets pounded from a fake tweet and Halozyme suffers from analyst downgrades. More
Barclays CEO Jenkins Buys Goodwill With Common Sense
Feb. 1, 2013, 2:46 pm EDT – Antony Jenkins' refusal to accept a bonus may be an obvious PR ploy, but who cares? His nod to the bank's misdeeds is refreshing. More
AMZN: The Cult of Not Yet
Jan. 31, 2013, 8:47 am EDT – Amazon keeps climbing on the vague promise of 'someday,' confounding bears and confusing analysts. But our cultural fascination with potential is pervasive ... and it extends far beyond stocks. More
Biotech Movers: Arena Gets Warned, MAP Gets an Offer
Jan. 28, 2013, 8:35 am EDT – Among last week's highlights, Europe raises questions about Arena's obesity drug, Belviq, and Allergan offers $958 million for MAP Pharmaceuticals. More
